SWOG clinical trial number
CTSU/C90601

A Randomized Double-Blinded, Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.

Closed
Phase
Abbreviated Title
Advanced TCC, Gemcitabine, Cisplatin +/- Bevacizumab, Ph III
Activated
08/15/2009
Closed
12/02/2014
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Cisplatin Gemcitabine hydrochloride Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2021

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

J Rosenberg;K Ballman;S Halabi;P Atherton;R Dreicer;C Holmes;W Stadler;E Plimack;T Flaig;R Dreicer;B Teply;J Pincus;S Tagawa;D Vaena;J Misleh;A Shipstone;A Mortazavi;M Morris Journal of Clinical Oncology Aug 1;39(22):2486-2496; May 14;JCO2100286. doi: 10.1200/JCO.21.00286. Online ahead of print

PMid: PMID33989025

2019

CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

J Rosenberg;K Ballman;S Halabi;C Watt;R Dreicer;T Flaig;M Morris J Clin Oncol 37(suppl; abstr 4503); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase